Celularity Inc. (Nasdaq: CELU) (“Celularity,” “the Company”), a
biotechnology company developing placental-derived allogeneic cell
therapies and biomaterial products, announced today that it will
present data on its proprietary extracellular matrices (ECM) at
ICBST23, the International Conference on Biomaterials Science and
Tissue Engineering (ICBSTE), to be held on 24-26 July in Osaka,
Japan.
The data will include benchtop and clinical case studies for
three Celularity human placental-derived advanced biomaterial
products:
- Biovance®, a decellularized,
dehydrated human amniotic membrane (DDHAM)
- Biovance® 3L, a tri-layer DDHAM
(DDHAM-3L)
- Interfyl®, a human connective tissue
matrix (CTM).
The data will be presented in an oral session entitled,
“Therapeutic Potential of Human Placental-Derived Biomaterials,” by
Anna Gosiewska, Ph.D., Vice President, Degenerative Disease
Research & Development, on Wednesday, July 26 at 9:00 a.m. JST/
8:00 p.m. EDT.
Benchtop data to be presented demonstrate that:
- DDHAM modulates macrophage behavior,
promoting polarization into M2 phenotype, and serves as a scaffold
for endogenous cell attachment and proliferation in wound
healing.
- DDHAM-3L supports human corneal
epithelial cell activity and attenuates an inflammatory response
over time.
- CTM supports tenocyte viability,
proliferation, and migration, while also maintaining phenotype and
attenuating the inflammatory response.
CTM also serves as a scaffold for the attachment and
proliferation of several cell types, including fibroblasts,
monocytes, and endothelial cells, and permits monocyte
differentiation into macrophages and vascular tube formation by
endothelial cells.
In clinical case studies, DDHAM has been used in tendon repair
and wound healing, DDHAM-3L has been used in the treatment of
anterior basement membrane dystrophy, and CTM has been used to
treat wounds and to support the repair of soft tissues.
Although these clinical case studies support the potential
therapeutic opportunities for these three human placental-derived
biomaterial products, additional clinical trials are needed to
compare the outcomes associated with different biomaterial
scaffolds in specific therapeutic applications.
“Celularity’s biomaterial products are manufactured using a
proprietary decellularization process that removes all residual
cellular components, cells, cell debris, DNA, growth factors, and
cytokines, while retaining the innate collagen framework with
essential extracellular matrix (ECM) molecules in its native
three-dimensional form. We believe our unique proprietary process
provides superior biocompatibility, and better supports
differentiated cell functions, as compared with other human
placental-derived biomaterials which may contain cellular
residuals,” said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO,
Chairman and Founder.
“Our state-of-the-art GMP/GTP on-site manufacturing capability
is one key aspect of Celularity’s novel business model, namely to
research and develop proprietary cellular and regenerative
therapeutics, including biomaterial products. We leverage a
diversified portfolio of therapeutic technologies all derived from
a single source material — the post-partum placenta. As the Company
that pioneered the use of placental-derived stem, progenitor, and
immune cells, and as an innovator in placental biomaterial product
development, we continually strive to meet unmet patient needs with
our novel biomaterials,” said Hariri.
About Celularity
Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park,
N.J., is a biotechnology company leading the next evolution in
cellular and regenerative medicine by developing, manufacturing,
and commercializing innovative biomaterial products derived from
the postpartum placenta. In addition, Celularity develops
allogeneic cryopreserved off-the-shelf placental-derived cell
therapies, including therapeutic programs using mesenchymal-like
adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR-T
cells), and genetically modified and unmodified natural killer (NK)
cells. These therapeutic programs target indications in autoimmune,
infectious and degenerative diseases, and cancer. Celularity
believes that by harnessing the placenta’s unique biology and ready
availability, it can develop therapeutic solutions that address
significant unmet global needs for effective, accessible, and
affordable therapies.
To learn more, visit celularity.com
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of The Private Securities Litigation Reform Act of
1995, as well as within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements other
than statements of historical facts are “forward-looking
statements,” including those relating to future events. In some
cases, you can identify forward-looking statements by terminology
such as “anticipate,” “believe,” “can,” “contemplate,” “continue,”
“could,” “estimate,” “expect,” “forecast,” “intends,” “may,”
“might,” “outlook,” “plan,” “possible,” “potential,” “predict,”
“project,” “seek,” “should,” “strive,” “target,” “will,” “would”
and the negative of terms like these or other comparable
terminology, and other words or terms of similar meaning. The
forward-looking statements in this press release include express or
implied statements regarding the potential application of
Celularity’s advanced biomaterials, Celularity’s ability to
differentiate its products from other human placental derived
biomaterial products, and Celularity’s ability to advance its
technology platform to develop therapeutic options for unmet
patient needs, among others. Many factors could cause actual
results to differ materially from those described in these
forward-looking statements, including but not limited to: the
inherent risks in biotechnological development, including with
respect to the development of novel biomaterial products and
cellular therapies, and the clinical trial and regulatory approval
process; and risks associated with Celularity’s current liquidity,
as well as developments relating to Celularity’s competitors and
industry, along with those risk factors set forth under the caption
“Risk Factors” in Celularity’s annual report on Form 10-K filed
with the Securities and Exchange Commission (SEC) on March 31,
2023, and other filings with the SEC. These risks and uncertainties
may be amplified by current economic situations, including
inflation, supply chain issues and overall economic uncertainty. If
any of these risks materialize or underlying assumptions prove
incorrect, actual results could differ materially from the results
implied by these forward-looking statements. There may be
additional risks that Celularity does not presently know, or that
Celularity currently believes are immaterial, that could also cause
actual results to differ from those contained in the
forward-looking statements. In addition, these forward-looking
statements reflect Celularity’s current expectations, plans, or
forecasts of future events and views as of the date of this
communication. Subsequent events and developments could cause
assessments to change. Accordingly, forward-looking statements
should not be relied upon as representing Celularity’s views as of
any subsequent date, and Celularity undertakes no obligation to
update forward-looking statements to reflect events or
circumstances after the date hereof, whether as a result of new
information, future events or otherwise, except as may be required
under applicable securities laws.
Celularity Contact:Paul Graves,
Chief Communications OfficerCelularity
Inc.paul.graves@celularity.com
Celularity (NASDAQ:CELU)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Celularity (NASDAQ:CELU)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024